The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mujtaba, M. G.
Right arrow Articles by Johnson, H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mujtaba, M. G.
Right arrow Articles by Johnson, H. M.
The Journal of Immunology, 2005, 175: 5077-5086.
Copyright © 2005 by The American Association of Immunologists

Treatment of Mice with the Suppressor of Cytokine Signaling-1 Mimetic Peptide, Tyrosine Kinase Inhibitor Peptide, Prevents Development of the Acute Form of Experimental Allergic Encephalomyelitis and Induces Stable Remission in the Chronic Relapsing/Remitting Form1

Mustafa G. Mujtaba2, Lawrence O. Flowers, Chintak B. Patel, Ravi A. Patel, Mohammad I. Haider and Howard M. Johnson

Department of Microbiology and Cell Science, University of Florida, Gainesville, FL 32611

We have previously characterized a novel tyrosine kinase inhibitor peptide (Tkip) that is a mimetic of suppressor of cytokine signaling 1 (SOCS-1) and inhibits JAK2 phosphorylation of the transcription factor STAT1{alpha}. We show in this study that Tkip protects mice against experimental allergic encephalomyelitis (EAE), an animal model for multiple sclerosis. Mice are immunized with myelin basic protein (MBP) for induction of disease. Tkip (63 µg) administered every other day suppressed the development of acute EAE in 75% of New Zealand White (NZW) mice. Furthermore, Tkip completely protected SJL/J mice, which where induced to get the relapsing/remitting form of EAE, against relapses compared with control groups in which >70% of the mice relapsed after primary incidence of disease. Protection of mice by Tkip was similar to that seen with the type I IFN, IFN-{tau}. Protection of mice correlated with lower MBP Ab titers in Tkip-treated groups as well as suppression of MBP-induced proliferation of splenocytes taken from EAE-afflicted mice. Cessation of Tkip and IFN-{tau} administration resulted in SJL/J mice relapsing back into disease. Prolonged treatment of mice with Tkip produced no evidence of cellular toxicity or weight loss. Consistent with its JAK2 inhibitory function, Tkip also inhibited the activity of the inflammatory cytokine TNF-{alpha}, which uses the STAT1{alpha} transcription factor. The data presented in this study show that Tkip, like the type I IFN, IFN-{tau}, inhibits both the autoreactive cellular and humoral responses in EAE and ameliorates both the acute and chronic relapsing/remitting forms of EAE.




This article has been cited by other articles:


Home page
J. Immunol.Home page
C. M. Prele, E. A. Woodward, J. Bisley, A. Keith-Magee, S. E. Nicholson, and P. H. Hart
SOCS1 Regulates the IFN but Not NF{kappa}B Pathway in TLR-Stimulated Human Monocytes and Macrophages
J. Immunol., December 1, 2008; 181(11): 8018 - 8026.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Qin, S. A. Niyongere, S. J. Lee, B. J. Baker, and E. N. Benveniste
Expression and Functional Significance of SOCS-1 and SOCS-3 in Astrocytes
J. Immunol., September 1, 2008; 181(5): 3167 - 3176.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
S. Madonna, C. Scarponi, O. De Pita, and C. Albanesi
Suppressor of cytokine signaling 1 inhibits IFN-{gamma} inflammatory signaling in human keratinocytes by sustaining ERK1/2 activation
FASEB J, September 1, 2008; 22(9): 3287 - 3297.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. W. Waiboci, C. M. Ahmed, M. G. Mujtaba, L. O. Flowers, J. P. Martin, M. I. Haider, and H. M. Johnson
Both the Suppressor of Cytokine Signaling 1 (SOCS-1) Kinase Inhibitory Region and SOCS-1 Mimetic Bind to JAK2 Autophosphorylation Site: Implications for the Development of a SOCS-1 Antagonist
J. Immunol., April 15, 2007; 178(8): 5058 - 5068.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Qin, C. A. Wilson, K. L. Roberts, B. J. Baker, X. Zhao, and E. N. Benveniste
IL-10 Inhibits Lipopolysaccharide-Induced CD40 Gene Expression through Induction of Suppressor of Cytokine Signaling-3
J. Immunol., December 1, 2006; 177(11): 7761 - 7771.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.